Opthea Limited
5 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD) (NCT04757636) | Opthea Limited | 2021-03-12 |
| OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) (NCT04757610) | Opthea Limited | 2021-03-12 |
| A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema (NCT03397264) | Opthea Limited | 2018-01-16 |
| A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD (NCT03345082) | Opthea Limited | 2017-11-06 |
Track Opthea Limited automatically
Every clearance here is in the API, with alerts when new ones post.